Nucleus Laboratories (India) Limted, a active public limited company, was established on 07 December 1999 in Lucknow, Uttar Pradesh, India. Engaging in drug formulation & development within the trade sector, it holds CIN: U24231UP1999PLC024944. Registered under ROC Roc Kanpur. it is unlisted. It has an authorized capital of ₹1.00 Cr and a paid-up capital of ₹1.00 Cr.
It upholds a compliant status. Its leadership includes Ashish Kumar Singh (Director), Debashish Saha (Director), Gyan Prakash Shrivastava (Director). Past directors included Santosh Kumar Singh, Shishir Kumar, Avadhesh Pratap Singh. It holds ₹3.00 M open charges and no settled loans. Its latest AGM occurred on 30 September 2024, with the balance sheet filed on 31 March 2024. It is based at Flat No. 101, First Floor,, Omaxe Avenue, Omaxe City, Lucknow, Uttar Pradesh, 226025.
U24231UP1999PLC024944
024944
07 December 1999
₹1.00 Cr
₹1.00 Cr
Roc Kanpur
Unlisted
Active
Explore comprehensive insights into Nucleus Laboratories (India) Limted — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Ashish Kumar Singh | Director | 27 Nov 2000 | Current |
| Debashish Saha | Director | 01 Jun 2023 | Current |
| Gyan Prakash Shrivastava | Director | 07 Mar 2022 | Current |
| Chandana Shrivastava | Director | 07 Mar 2022 | Current |
| Himani Shukla | Director | 01 Aug 2025 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Director | 30 Nov 2016 | Past |
| Pramod Abcsdd | Director | 29 Sep 2009 | Past |
| Pramod Abcsdd | Additional Director | 01 Jun 2023 | Past |
| Pramod Abcsdd | Additional Director | 01 Jun 2023 | Past |
| Pramod Abcsdd | Additional Director | 30 Nov 2016 | Past |
| Pramod Abcsdd | Director | 28 Mar 2019 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Nucleus Laboratories (India) Limted, for the financial year ended 2020, experienced significant reduction in revenue, with a 16.11% decrease. The company also saw a substantial fall in profitability, with a 931.97% decrease in profit. The company's net worth Soared by an impressive increase of 240.8%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2020, Nucleus Laboratories (India) Limted had a public holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
₹3,000,000.00
₹0
| Date | Lender | Amount | Status |
|---|---|---|---|
| 02 Jun 2018 | Bank Of India | ₹3.00 M | Open |
Explore comprehensive loan charge details -
Unlock and access historical data on people associated with Nucleus Laboratories (India) Limted, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Gain comprehensive insights into the Deals and Valuation data of Nucleus Laboratories (India) Limted, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nucleus Laboratories (India) Limted's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Progress on Himani Shukla was appointed as a Director was appointed as a Director on 01 Aug 2025 & has been associated with this company since 3 months 27 days . was documented.
Progress on Nucleus Laboratories (India) Limted last Annual general meeting of members was held on 30 Sep 2024 as per latest MCA records. was documented.
The activity Nucleus Laboratories (India) Limted has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Kanpur. was completed.
Debashish Saha was appointed as a Director was appointed as a Director on 01 Jun 2023 & has been associated with this company since 2 years 5 months . was recorded as a recent event.
Gyan Prakash Shrivastava was appointed as a Director was appointed as a Director on 07 Mar 2022 & has been associated with this company since 3 years 8 months . was recorded as a recent event.
The activity Chandana Shrivastava was appointed as a Director was appointed as a Director on 07 Mar 2022 & has been associated with this company since 3 years 8 months . was completed.
The CIN of Nucleus Laboratories (India) Limted is U24231UP1999PLC024944.
Nucleus Laboratories (India) Limted is headquartered at Flat No. 101, First Floor,, Omaxe Avenue, Omaxe City, Lucknow, Uttar Pradesh, 226025.
Nucleus Laboratories (India) Limted was incorporated on 07 December 1999.
The current directors of Nucleus Laboratories (India) Limted are
The primary industry of Nucleus Laboratories (India) Limted is Trade.
Nucleus Laboratories (India) Limted is unlisted.
The authorized capital of Nucleus Laboratories (India) Limted is ₹1.00 Cr, and the paid-up capital is ₹1.00 Cr.
The compliance status of Nucleus Laboratories (India) Limted is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX